Pause, Not Rewind

Pause, Not Rewind COVID-19 Has Slowed or Halted HIV Studies, But Research Must Continue by Jeannie Wraight F or most of the U.S. and all but a few...

Expediting Research

GlaxoSmithKline (GSK) and the University of North Carolina at Chapel-Hill (UNC) will launch a jointly owned novel HIV Cure Center, as well as a...

IV Drug Users & HIV Vaccine Response

Everyone Counts Differences in intravenous drug users may affect their response to an HIV vaccine by Jeannie Wraight Prevention strategies such as Treatment as Prevention, PrEP, syringe...

Talking “Cure”

Nobel Prize Laureate and world renowned HIV researcher Françoise Barré-Sinoussi recently made the statement that she does not believe an HIV cure is possible....

APPROACH Study

Mosaic Design APPROACH, a preventive vaccine study, seeks to address more than one clade by Jeannie Wraight Over the past thirty-plus years, strategies such as Treatment as...

Countdown to a Cure

by Jeannie Wraight As part of the Countdown to a Cure Initiative, amfAR (The Foundation for AIDS Research) will direct $20 million, of a $100...

Questioning the Cure

When first discussing the potential of writing a monthly column on HIV cure, my editor here at A&U Magazine asked a very valid question....

Targeting HIV Reservoirs

Hiding Place One focus of the amfAR 2016 CURE Summit targeted HIV reservoirs by Jeannie Wraight This year, amfAR marked World AIDS Day with the 2016 HIV...

David Evans

Risk & Reward Activist David Evans weighs in on next steps in cure advocacy & research by Jeannie Wraight In the late 1980s and throughout the ’90s,...

BIT225: HIV VPU Inhibitor Candidate

Contender in the Ring A novel HIV therapy targets & eradicates one cell type in the viral reservoir by Jeannie Wraight BIT225, an HIV VPU inhibitor, has...

LATEST POSTS

$210M Funding Opportunity for CBOs

CDC Announces $210M Funding Opportunity for CBOs On September 28, 2020, the Centers for Disease Control and Prevention (CDC) announced the availability in fiscal 2021...

High Flight